SharePoint
A- A A+

For Patients & Visitors

Find a Doctor

Find a Doctor

Professor Chng Wee Joo

Photo of Professor Chng Wee Joo
Credential:
MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS
Designation:
Director, National University Cancer Institute, Singapore
Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Leader, Haematologic Malignancy Tumour Group, National University Cancer Institute, Singapore (NCIS)
Professor, Yong Loo Lin School of Medicine, National University of Singapore (NUS)
Deputy Director, Cancer Science Institute of Singapore, National University of Singapore (NUS)
Provost's Chair Professor, Yong Loo Lin School of Medicine, National University of Singapore (NUS)

Specialty:
Cancer
Sub Specialty:
Haematology, Haematology-Oncology
Medical and Surgical Conditions:
Blood Cancer, Multiple Myeloma
Special Interest:
Multiple Myeloma
Lymphoma
Institution:
National University Hospital
National University Cancer Institute, Singapore
National University Health System
Prof Chng obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. Fellowship training in haematology was completed in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics. His current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.

Awards and Honours

2017 - NUS YLL SOM Outstanding Researcher of the Year Award
2017 - NMRC Senior Translational (STaR) Research Award
2016 - 26th Seah Cheng Siang Memorial Lecture
2016 - NMEA National Outstanding Clinician-Scientist Award
2012 - NMRC Clinician Scientist (Senior) Award
2011 - Chua Hua Toh Memorial Gold Medal (Best Graduate Thesis in Life Science)
2011 - NUS Young Research Award
2010 - YLL SOM Faculty Outstanding Researcher Award (Young Researcher Category)
2009 - JCI The Outstanding Young Persons Award
2008 - NMRC Clinician Scientist Award
2007 - Celgene Future Leaders in Haematology Award
2007 - SMJ Best Reviewer Award 2006
2006 - 2007 Multiple Myeloma Research Foundation
2006 - Singapore Medical Journal Best Research Paper 2005 (Second Prize)
2004 - 2006 A*Star International Fellowship
2004 - Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation
2003 - Courage Star
2002 - Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation

Professional Memberships

American Society of Haematology
American Association of Cancer Research
International Myeloma Working Group
Asian Myeloma Network
Singapore Society of Haematology

Research and Publications

1. WJ Chng, SA Van Wier, G Ahmann, et al. A validated FISH Trisomy Index Demonstrates the Hyperdiploid and non-hyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156-2161. [IF – 10.56]

2. WJ Chng, G Ahmann, K Henderson, et al. Clinical implication of centrosome abnormalities in Plasma Cell Neoplasm. Blood 2006; 107: 3669-3675. [IF – 10.56]

3. WJ Chng, S Kumar, S Van Wier, et al. Molecular dissection of hyperdiploid myeloma using gene expression profiling. Cancer Res 2007; 67: 2982-2989. [IF – 7.54]

4. WJ Chng, E Braggio, R Valdez, G Mulligan, B Bryant, E Remstein, A Dogan, R Fonseca. The centrosome index is a powerful prognostic marker in multiple myeloma and identifies a cohort of patients that may benefit from aurora kinase inhibition. Blood 2008; 111: 1603-1609. [IF – 10.56]

5. WJ Chng, TH Chung, S Van Wier, et al. Correlation between Array-Comparative Genomic Hybridization Defined Genomic Gains and Losses and Survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24: 833-842. [IF – 8.30]

6. WJ Chng, GF Huang, TH Chung, et al. Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011 25 :1026-35 [IF – 8.30]

7. SB Ng, V Selvarajan, G Huang, J Zhou, AL Feldman, M Law, YL Kwong, N Shimizu, Y Kagami, K Aozasa, M Salto-Tellez, WJ Chng. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011; 223: 496-510. 

8. J Zhou, C Bi, LL Cheong, S Mahara, SC Liu, KG Tay, TL Koh, Q Yu, WJ Chng. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011; 118: 2830-9. [IF – 10.56]

9. SB Ng, J Yan, G Huang, V Selvarajan, JL Tay, B Lin, C Bi, J Tan, YL Kwong, N Shimizu, K Aozasa, WJ Chng. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 201; 118: 4919-29. [IF – 56]

10. J Yan, SB Ng, JL Tay, B Lin, TL Koh, J Tan, V Selvarajan, SC Liu, C Bi, S Wang, SN Choo, N Shimizu, G Huang, Q Yu and WJ Chng. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013; 121: 4512-4520

11. WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, J San Miguel, P Sonneveld, S Umani, BDG Durie, H Avet-Loiseau on Behalf of the International Myeloma Working Group. IMWG Consensus on Risk Stratification in Multiple Myeloma. Leukemia 2014; 28: 269-77



Contact

Appt Tel:
Fax:
+65 6777 4413